Publications by authors named "Georges Sideris"
Article Synopsis
- Inflammatory processes significantly worsen myocardial damage during ischemia-reperfusion injury in STEMI, leading to serious complications like heart failure and poor recovery.
- Colchicine, known for its strong anti-inflammatory effects, has shown a promising 50% reduction in infarct size in a phase II trial, compared to placebo, for acute STEMI patients undergoing primary percutaneous coronary intervention (PPCI).
- The ongoing COVERT-MI trial aims to confirm these findings by comparing a short course of colchicine treatment to placebo in STEMI patients, measuring infarct size and other cardiac health indicators over 5 days.
Background: Little is known about the association between provision of post-resuscitation care and prognosis of out-of-hospital cardiac arrest (OHCA) in elderly patients. Previous studies have suggested futility after 65 years of age.
Objectives: We aimed to evaluate the association of early coronary angiogram (CAG) followed if necessary by percutaneous coronary intervention (PCI), with favorable outcome after OHCA among elderly patients, compared to younger patients.
Objectives: The purpose of this study was to determine whether the speed of response to clopidogrel loading predicts the final degree of response.
Background: Fast inhibition of platelet aggregation is important in the setting of acute coronary syndromes and percutaneous coronary intervention, but its association with the final degree of inhibition is not well established.
Methods: We performed a post hoc analysis of the ALBION study; early kinetic profiles of adenosine diphosphate 20 micromol/l maximal platelet aggregation (MPA) and DeltaMPA (with baseline sample as reference) were studied at 8 time points within the 24 h after clopidogrel loading (300, 600, or 900 mg) in non-ST-segment elevation acute coronary syndrome patients.
Objectives: We sought to compare the antiplatelet effects of three clopidogrel loading doses (LDs).
Background: Administration of a 300-mg clopidogrel LD is beneficial in situations requiring rapid platelet inhibition. Whether higher LDs can provide further benefits remains unknown.